Topic: shareholder activism
Last year, activists began pushing troubled Acorda Therapeutics to sell—and it looks as if the company may be heeding that advice.
Alexion and activist investor Elliott Management are putting their differences aside.
Shire CEO Flemming Ornskov acknowledged he could have done more to help investors understand the transition the company is making.
Industry watchers have tabbed Alexion as a potential activist target. And one prominent activist reportedly wants to take advantage of the opportunity.
Shire has hinted that a spinoff of its neuroscience unit may be in the works. But one U.S. hedge fund wants more.
Even after Mylan's board won re-election last week, still-unappeased shareholders aren’t giving up on their demands for a housecleaning.
Mylan's pushing ISS to say whether it will back controversial Chairman Robert Coury for reelection, but the shareholder adviser isn't talking.
Last October, Depomed switched up its board to appease activist Starboard Value. But Starboard didn’t stop there, and now Depmed has a new CEO.
Bill Ackman’s Valeant chapter is finally coming to a painful close. The activist investor bailed out of the company, selling his 27.2M shares for just about $11 apiece.
A faith-based investor group’s attempt to learn more about drug pricing is hitting a wall.